{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:51:26Z","timestamp":1769125886595,"version":"3.49.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.idc.2020.02.009","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T01:10:38Z","timestamp":1587604238000},"page":"341-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Hepatitis B Virus Reactivation Potentiated by Biologics"],"prefix":"10.1016","volume":"34","author":[{"given":"Eiichi","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike T.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2020.02.009_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2020.02.009_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cgh.2013.09.062","article-title":"Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population","volume":"12","author":"Gordon","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib8","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2020.02.009_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2020.02.009_bib10","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2020.02.009_bib12","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.idc.2020.02.009_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","article-title":"Structural organization of the hepatitis B virus minichromosome","volume":"307","author":"Bock","year":"2001","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.idc.2020.02.009_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.idc.2020.02.009_bib15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.1840180605","article-title":"Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B","volume":"18","author":"Fong","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nm.3251","article-title":"Pathogenesis of chronic viral hepatitis: differential roles of T\u00a0cells and NK cells","volume":"19","author":"Rehermann","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.idc.2020.02.009_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.idc.2020.02.009_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2020.02.009_bib19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1084\/jem.179.3.841","article-title":"Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis","volume":"179","author":"Gonz\u00e1lez-Amaro","year":"1994","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.idc.2020.02.009_bib20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection-natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.009_bib21","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.idc.2020.02.009_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.idc.2020.02.009_bib23","doi-asserted-by":"crossref","first-page":"926836","DOI":"10.1155\/2014\/926836","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","volume":"2014","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.idc.2020.02.009_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.idc.2020.02.009_bib25","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.idc.2020.02.009_bib26","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.idc.2020.02.009_bib27","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2020.02.009_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.idc.2020.02.009_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.009_bib30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.idc.2020.02.009_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1479-5876-5-27","article-title":"Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T\u00a0cells (Tem) and relative preservation of central memory T\u00a0cells (Tcm) in psoriasis","volume":"5","author":"Chamian","year":"2007","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.idc.2020.02.009_bib32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","article-title":"Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.idc.2020.02.009_bib33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A\u00a0randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.009_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others","volume":"53","author":"Puig","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.idc.2020.02.009_bib35","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1478-3231.2012.02764.x","article-title":"Pivotal roles of the interleukin-23\/T helper 17 cell axis in hepatitis B","volume":"32","author":"Huang","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.idc.2020.02.009_bib36","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.idc.2020.02.009_bib37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety pro\ufb01le of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.idc.2020.02.009_bib38","first-page":"1433","article-title":"Natalizumab in the treatment of Crohn's disease patients","volume":"17","author":"Pagnini","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.idc.2020.02.009_bib39","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.idc.2020.02.009_bib40","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1212\/NXI.0000000000000072","article-title":"Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis","volume":"2","author":"Hillen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.idc.2020.02.009_bib41","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2020.02.009_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.06.017","article-title":"The interleukin (IL)-1 cytokine family--balance between agonists and antagonists in inflammatory diseases","volume":"76","author":"Palomo","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.idc.2020.02.009_bib43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.idc.2020.02.009_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib45","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.009_bib46","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.4049\/jimmunol.178.5.2714","article-title":"PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver","volume":"178","author":"Maier","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.idc.2020.02.009_bib47","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1053\/j.gastro.2012.08.041","article-title":"Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T\u00a0cells against HBV, but not HCV","volume":"143","author":"Fisicaro","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2020.02.009_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib49","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.009_bib50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.009_bib51","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.009_bib52","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.idc.2020.02.009_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment","volume":"47","author":"Ikeda","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.idc.2020.02.009_bib54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-009-0386-2","article-title":"Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review","volume":"90","author":"Kang","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.idc.2020.02.009_bib55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5005\/jp-journals-10018-1147","article-title":"Hepatitis B virus reactivation under treatment with nilotinib","volume":"5","author":"Temel","year":"2015","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.idc.2020.02.009_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.05.032","article-title":"Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients","volume":"117","author":"Yao","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.idc.2020.02.009_bib57","article-title":"In\u00a0vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T\u00a0cells in combination with cetuximab or panitumumab","author":"Caratelli","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.idc.2020.02.009_bib58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.idc.2020.02.009_bib59","first-page":"2225","article-title":"Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in\u00a0vitro and in\u00a0vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol Rep"},{"key":"10.1016\/j.idc.2020.02.009_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T\u00a0cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.idc.2020.02.009_bib61","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","article-title":"Hepatitis B virus reactivation associated with ruxolitinib","volume":"93","author":"Shen","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.idc.2020.02.009_bib62","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.009_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2016.06.001","article-title":"Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation","volume":"77","author":"Frazer-Abel","year":"2016","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.idc.2020.02.009_bib64","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib65","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.idc.2020.02.009_bib66","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","article-title":"Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations","volume":"21","author":"Mori","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.idc.2020.02.009_bib67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10067-013-2450-9","article-title":"Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy-a report of long-term follow-up of serial cases and literature review","volume":"33","author":"Xuan","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.idc.2020.02.009_bib68","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.idc.2020.02.009_bib69","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","article-title":"Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists","volume":"16","author":"Pauly","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib70","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjd.12120","article-title":"Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient","volume":"168","author":"Koskinas","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.idc.2020.02.009_bib71","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0609.2004.00375.x","article-title":"Hepatitis B virus reactivation and alemtuzumab therapy","volume":"74","author":"Iannitto","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.idc.2020.02.009_bib72","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2020.02.009_bib73","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/10245332.2017.1321882","article-title":"Hepatitis B reactivation in patients receiving targeted therapies","volume":"22","author":"Chang","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.idc.2020.02.009_bib74","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","article-title":"Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?","volume":"131","author":"Giammarco","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.idc.2020.02.009_bib75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00277-018-3405-7","article-title":"Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment","volume":"98","author":"Gill","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.idc.2020.02.009_bib76","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","article-title":"Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis","volume":"30","author":"Zurawska","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.idc.2020.02.009_bib77","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1008206519571","article-title":"Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma","volume":"9","author":"Clark","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.idc.2020.02.009_bib78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1572-0241.1999.00808.x","article-title":"Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection","volume":"94","author":"Ahmed","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.idc.2020.02.009_bib79","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1572-0241.2001.03824.x","article-title":"Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B","volume":"96","author":"Cainelli","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.idc.2020.02.009_bib80","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2147\/DDDT.S126742","article-title":"Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy","volume":"11","author":"Ogawa","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.idc.2020.02.009_bib81","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17474124.2017.1386554","article-title":"Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics","volume":"11","author":"Hsu","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2020.02.009_bib82","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/hep.24308","article-title":"Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection","volume":"53","author":"Nguyen","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib83","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.23461","article-title":"Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial\/ethnic differences, and viral interactions","volume":"51","author":"Bini","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib84","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/cid\/civ474","article-title":"Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir","volume":"61","author":"Collins","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.02.009_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.29109","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2020.02.009_bib86","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","article-title":"Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV","volume":"154","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2020.02.009_bib87","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2893.2009.01249.x","article-title":"Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007","volume":"17","author":"Spradling","year":"2010","journal-title":"J\u00a0Viral Hepat"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:18:07Z","timestamp":1760195887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0891552020300118"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.009","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B Virus Reactivation Potentiated by Biologics","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}